If this mail is unreadable,  click here
Hot Off the Press News: Announcing the late-breaking abstracts

Following the deadline of late breaking abstract submission, 37 abstracts have been selected for the Presidential and proffered paper sessions. Due to a number of high quality abstracts, extra proffered paper sessions have been added:

  1. Immunotherapy of Cancer I, 09:15-10.25, 27 Sep
  2. Melanoma and Skin Cancer,  11.30-12.30, 27 Sep
  3. Early Drug Development II, 17:00-18:10, 27 Sep

Highlights of this year’s late breaking abstracts will include in the Presidential sessions:

Presidential session I
CheckMate 025: a randomised, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC); P. Sharma, B. Escudier, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas, S.S. Tykodi, J.A. Sosman, G. Procopio, E.R. Plimack, D. Castellano1, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T.C. Gauler, T. Ueda, L.A. Xu, I.M. Waxman, R.J. Motzer
Metastatic Renal Cell Carcinoma has been seen as an immune responsive maglinancy, these results of the phase III will show that comparing nivolumab with everolimus in patients with previously treated metastatic renal cell carcinoma will change the treatment paradigm.

Presidential session II
177-Lu-Dotatate significantly improves progression-free survival in patients with mid gut neuroendocrine tumours: Results of the phase III NETTER-1 trial; J. Strosberg, E. Wolin, B. Chasen, M. Kulke, D. Bushnell, M. Caplin, R.P. Baum, E. Mittra, T. Hobday, A. Hendifar, K. Oberg, M. Lopera Sierra, P. Ruszniewski, D. Kwekkeboom
Reporting for the first time the results of NETTER-1, first Phase III multinational, randomised, controlled trial evaluating 177-Lu-Dotatate versus best standard of care in patients with inoperable, progressive, somatostatin receptor positive mid gut Neuroendocrine tumours. This population has currently very limited treatment options, these results will show an improved progression free survival for these patients.

Presidential III
5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group; D. Dearnaley, I. Syndikus, H. Mossop, A. Birtle, D. Bloomfield, C. Cruickshank, J. Graham, S. Hassan, V. Khoo, J. Logue, H. Mayles, J. Money-Kyrle, O. Naismith, M. Panades, H. Patterson, C. Scrase, J. Staffurth, J. Tremlett, C. Griffin, E. Hall
This potentially practice changing phase III clinical trial was conducted to evaluate the standard versus hypofractionated radiotherapy in men with localised prostate cancer. This is the largest randomised controlled treatment trial undertaken in this disease recruiting over 3200 participants. With a median of over 5 years follow-up, it is the first presentation of efficacy results from the trial.

The overview of the presidential sessions and late breaking proffered paper sessions can be found on the searchable programme.
(Please note all late breaking, best, oral and abstracts selected for the media programme will be available online only on the day of the presentation)

Timebombs in oncology: Cancer Survivorship

Breakthroughs in research and state-of-the-art clinical practice have made it possible for cancer to be treated with increasingly improved outcomes. Studies show that survival time has been rising to reach the 10-year mark for several major cancers since the 1970s. Smaller yet significant improvements are also reported for other selected types of the disease. Today, we can finally speak of effective treatment and life after a cancer diagnosis.

This great achievement comes at a cost. First and foremost, survivors face a range of physical, quality of life and participation issues. For health and social systems, there is the need to adapt so as to ensure the best possible solution that each survivor deserves.

Read more…

Sharpen your leadership skills and get certified!
What’s hot in lung and breast cancer research and clinical care?

This year’s European Cancer Congress (ECC2015) will play host to some of the best research from around the world and will cover all aspects of cancer from basic science to clinical care. The most common tumour types will be represented, as will some of the rarest, ensuring that regardless of speciality there will be something for everyone.

For this e-newsletter, we spoke to experts in two of the most popular areas in terms of abstract submissions, lung and breast cancer, to see what they thought about the upcoming Congress.

Read more…

Get to know each other at ECC2015!
Programme Highlights

ECC2015 has been designed in order to give the opportunity to share new ideas in a vibrant environment.

Interesting topics will be presented so keep an eye on our Searchable Programme and make sure you do not miss out on important discussions concerning Breast Cancer, Cancer Prevention and Screening, Immunotherapy of Cancer, Melanoma and Skin Cancer to name but a few.

Through our Searchable Programme you will be able to make an easy selection by date, track, type session, author or keyword and, at the same time, you will have the possibility to create your personal agenda.

You can also access the Searchable Programme from our App. If you do not have the App yet, download it here. 

Things to remember:

  • The ECCO App can be used offline
  • Do not uninstall the App after the event since any future congresses will be available there
  • The App is available for iOS and Android
  • For any questions, please refer to our FAQ session
  • There is no printed programme book
Will you Go the Extra Mile?

For the first time ever, ECC2015 will undertake a public education engagement exercise in its host city of Vienna that establishes the awareness of the largest European Cancer Congress gathering this year, profiling its members and promoting all the outstanding work that our community is doing in advancing the treatment of cancer. We’re all going the extra mile to develop new treatment methods, new procedures or presenting the latest practice-changing data and we want everyone to join in.

As part of the campaign, we have partnered with the annual Cancer research Run of Vienna, which will happen during the Congress on Saturday 26 September, and we will use the opportunity to promote an educational campaign on healthy living for Vienna citizens, and asking the public to go the extra mile either by taking part in the run, or simply to donate to the Vienna Cancer Run. As part of the legacy of #ECC2015, we are developing an online payment platform for the Vienna Cancer Run, which will make it even easier for people to raise much needed revenue, get sponsored or just donate online.

A series of inflatable running shoes will be strategically placed across the city promoting the Congress and making people aware that the world’s leading oncology community are in town presenting the latest ground-breaking data and making a difference in the development of cancer treatment.

What will you do to #gotheextramile?

Official newsletter issue 6
25 August 2022
  Did you know  

With a thriving economy, a stable political system, Austria’s beautiful countryside and its cultural diversity, all contribute to a high-quality lifestyle for locals and tourists alike. Vienna also has a very good reputation for outstanding international transport links, public transport, services, hotels and restaurants, and good standards of cleanliness and security.


Read all the previous newsletter issues here



Avenue E. Mounier 83
1200 Brussels
Tel: +32 2 775 02 01
Fax: +32 2 775 02 00

Email: [email protected]
Website: ECC2015
Hashtag: #ECC2015

© 2015 ECCO all right reserved Disclaimer Unsubscribe Contact